ArticleSkeletal muscle2026
FGF2 rescues denervation-induced muscle atrophy in Ambystoma mexicanum.
Article in Skeletal muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDenervation occurs as a consequence of disease or injury and is typically accompanied by skeletal muscle atrophy. Although the relationship between nerves and muscle atrophy has been studied, the direct molecular contributions of nerves remain unclear.
methodsWe used the axolotl (Ambystoma mexicanum), a vertebrate with robust regenerative capacity and optically accessible musculature, to investigate the role of nerve-derived signals in muscle maintenance.
resultsForelimb denervation produced significant muscle atrophy in axolotls. Quantitative imaging showed that reduced muscle fiber size—rather than fiber loss—underlies this atrophy. To investigate the molecular basis of denervation-induced atrophy, we focused on fibroblast growth factor 2 (FGF2), a nerve-derived factor previously implicated in axolotl limb regeneration. Electroporation of FGF2 into denervated muscles significantly preserved muscle fiber size compared with controls. Conversely, pharmacological inhibition of FGF signaling with SU5402 reduced fiber size, supporting a requirement for FGF signaling in maintaining muscle mass.
conclusionsThese findings demonstrate that FGF2 is sufficient to mitigate denervation-induced muscle atrophy and support a requirement for FGF signaling in the maintenance of muscle mass. Together with the neural expression of Fgf2, our data support a model in which nerve-derived FGF2 contributes to muscle maintenance. This work positions the axolotl as a tractable model for dissecting neuromuscular signaling and identifies FGF2 as a promising therapeutic candidate for neuromuscular atrophy. Understanding this mechanism may inform strategies to preserve muscle mass after nerve injury or in neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.